Literature DB >> 16985819

Dawning of the age of chemotherapy for prostate cancer.

Stephen J Freedland1, Alan W Partin.   

Abstract

Entities:  

Year:  2005        PMID: 16985819      PMCID: PMC1477569     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


× No keyword cloud information.
  3 in total

1.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

Authors:  P W Kantoff; S Halabi; M Conaway; J Picus; J Kirshner; V Hars; D Trump; E P Winer; N J Vogelzang
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

2.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

3.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.